Skip to main content

Table 1 Sequential serological, biochemical and virological findings in an HIV-infected individual with markers of prior HBV infection at baseline.

From: Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy

Characteristics Date (month/year)
  10/85 11/87 10/001 01/011 05/011 11/061 01/071 01/081 05/09 12/09 02/10 02/10 03/10 04/10 05/10 07/10
HBsAg (IU/ml) NEG NEG 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -- 168 183 132 66 0.1 0.0
Anti-HBs (mIU/ml) POS POS <10 <10 <10 <10 <10 <10 <10 -- 140 124 87 61 50 24
Anti-HBc POS POS POS POS POS POS POS POS POS -- POS POS POS -- POS POS
Anti-HBc IgM NEG NEG -- -- -- -- -- -- -- -- POS POS POS NEG -- --
HBeAg NEG NEG -- -- -- -- -- -- -- -- POS NEG NEG -- -- --
Anti-HBe NEG NEG -- -- -- -- -- -- -- -- POS POS POS -- -- --
HBV DNA (IU/ml) -- -- R (3) R (7) 19 NR NR NR NR -- 88,185 5,622 998 26 R (4) NR
AST (U/l) 17 19 31 58 30 20 21 23 28 80 2,702 143 41 -- 23 19
ALT (U/l) 14 16 35 68 37 14 14 14 19 111 2,577 306 42 -- 17 21
CD4+ T (cells/µl) 891 883 48 29 48 478 580 516 513 304 291 -- -- -- 423 333
HIV-RNA 2 (copies/ml) -- -- 147,018 222,107 146,707 <50 <50 NR NR 80,558 -- -- 734 -- NR NR
Antiretroviral therapy Naive Naive No3 No3 No3 Yes4 Yes4 Yes4 Yes4 No5 No5 Yes6 Yes6 Yes6 Yes6 Yes6
  1. IU/ml = International Units/milliliter; mIU/ml = International milliunits/ml; U/l = Units/liter; NEG = negative; POS = positive; R = reactive below cut-off (<10IU/ml); HBV DNA calculated by the regression curve in brackets; NR = not reactive; -- = not determined.
  2. 1molecular and serological markers of HBV infection were retrospectively determined in February 2010 using automated Abbott HBV RealTime and Abbott ARCHITECT HBV assays, respectively
  3. 2HIV viremia was evaluated by Versant HIV RNA assay 3.0 (bDNA; Siemens Healthcare Diagnostics, Deerfield, IL) up to 01/2007 and by Abbott HIV RealTime since 01/2008.
  4. 3Previous antiretroviral therapy (Didanosine, Lamivudine, Nevirapine) was started on 04/2000 and interrupted on 08/2000; Lamivudine daily dose was 300 mg.
  5. 4Therapy was resumed in 02/2002 with different drug combinations including Lamivudine (300 mg daily) with or without Tenofovir (245 mg daily).
  6. 5Therapy (Lamivudine and Atazanavir) was interrupted on 10/2009.
  7. 6Therapy was resumed in 02/2010, including co-formulated Emtricitabine/Tenofovir (200/245 mg daily) plus boosted Darunavir.